Image

Cervical Fixation Surgery Cervical Collar for Management of Hirayama Disease: A Randomized Study

Cervical Fixation Surgery Cervical Collar for Management of Hirayama Disease: A Randomized Study

Recruiting
18-60 years
All
Phase N/A

Powered by AI

Overview

The goal of this clinical trial] is to compare cervical collar versus neck stabilization surgery in diagnosed patients of Hirayama disease who have been reporting worsening of problems in the past six months. The main question[s] it aims to answer are:

• Is cervical stabilization surgery (Posterior cervical fixation) superior to conservative management in the form of cervical collar placement in patients with progressive Hirayama disease, observed at six months after intervention

Participants will have equal chance to:

  • Undergo cervical fixation surgery
  • Cervical collar management The investigators will study and compare the efficacy of both treatments upto six months after intervention

Description

  1. Study design:

Prospective randomized open blinded endpoint (PROBE), phase III study

2. Inclusion criteria:

All the following:

  1. Age ≥ 18 years
  2. Patients with Hirayama disease as per the following criteria (All of the following) (16):
  3. Clinical evidence of wasting and weakness confined to one limb (EMG evidence of denervation in the opposite limb will not be a reason for exclusion)
  4. Progressive course, or initial progression followed by stationary course; and
  5. No evidence of a compressive lesion of the spinal cord.
  6. Disease duration of ≤4 years
  7. Progression of clinical symptoms in the past six-months c. Exclusion criteria:

Any of the following:

  1. Refusal to consent for randomization 2) Not willing to come for three- and six-months follow-up e. Procedures at baseline:
    1. Clinical, electrophysiology and autonomic function assessments:

After the clinical diagnosis by inclusion criteria, the patients will undergo a detailed clinical examination (as per the case record form (CRF), which includes power, autonomic features, grip strength), and the objective assessment of the electrophysiological parameters

2. Radiological assessment:

All patients will undergo MR imaging on a 1.5 T MR scanner (Optima 450w, General Electric, Milwaukee, USA), using an 8-channel cervical-thoracic-lumbar array spine coil. The imaging will include axial and sagittal T2-WIs and post-gadolinium T1+C in flexion, neutral and extension positions. In addition, DTI protocol will include sagittal and axial acquisition of cervical cord in neutral position. MR-DTI data will process on a dedicated workstation (Advantage Windows workstation, GE Healthcare, WI, USA) using commercially available software (Functool 14.3.01, GE HealthCare, WI, USA). After co-registration of raw images to correct the motion and distortion artefacts, the ADC and FA images will be generated. The mean, minimum and maximum values of FA and ADC will be recorded from region of maximum cord compression/ T2-hyperintensity.

The investogators will get a cervical spine radiograph at the time of discharge and at 6 months.

3. Surgical procedure:

The patients who are randomized to undergo posterior cervical fixation will be admitted in Neurosciences Centre, All India Institute of Medical Sciences, New Delhi. These patients will undergo routine preoperative work up, including routine blood investigations and a detailed preanesthetic checkup (PAC). These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.

Eligibility

Inclusion Criteria:

  • All the following:
    1. Age ≥ 18 years
    2. Patients with Hirayama disease as per the following criteria (All of the following) (16):
      1. Clinical evidence of wasting and weakness confined to one limb (EMG evidence of denervation in the opposite limb will not be a reason for exclusion)
      2. Progressive course, or initial progression followed by stationary course; and
      3. No evidence of a compressive lesion of the spinal cord.
    3. Disease duration of ≤4 years
    4. Progression of clinical symptoms in the past six-months

Exclusion Criteria:

  • Any of the following:
    1. Refusal to consent for randomization
    2. Not willing to come for three- and six-months follow-up

Study details
    Hirayama Disease

NCT05959980

All India Institute of Medical Sciences, New Delhi

17 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.